LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Aandelen Lijst・Ovid therapeutics Inc

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

2.73 -1.44

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.65

Max

2.79

Belangrijke statistieken
By Trading Economics
Inkomsten	22M 9.7M
Verkoop	586K 718K
Winstmarge	1,345.822
Werknemers	23
EBITDA	-152K -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+80.94% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	368M 507M
Vorige openingsprijs	4.17
Vorige sluitingsprijs	2.73

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.275 / 0.33 Steun & Weerstand

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 mei 2026, 23:58 UTC

Winsten

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mei 2026, 22:57 UTC

Winsten

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mei 2026, 23:52 UTC

Winsten

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mei 2026, 23:45 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mei 2026, 23:39 UTC

Marktinformatie

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mei 2026, 23:28 UTC

Marktinformatie

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mei 2026, 23:11 UTC

Winsten

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mei 2026, 23:06 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mei 2026, 23:05 UTC

Winsten

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mei 2026, 23:04 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mei 2026, 23:03 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mei 2026, 23:03 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mei 2026, 23:02 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mei 2026, 23:00 UTC

Marktinformatie

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mei 2026, 22:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 mei 2026, 22:45 UTC

Marktinformatie

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mei 2026, 22:42 UTC

Winsten

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mei 2026, 22:33 UTC

Winsten

Acquisities, Fusies, Overnames

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mei 2026, 22:32 UTC

Winsten

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mei 2026, 22:31 UTC

Winsten

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mei 2026, 22:31 UTC

Winsten

Macquarie: 68% of FY Income From International >MQG.AU

7 mei 2026, 22:30 UTC

Winsten

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mei 2026, 22:30 UTC

Winsten

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mei 2026, 22:29 UTC

Winsten

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mei 2026, 22:28 UTC

Winsten

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mei 2026, 22:28 UTC

Winsten

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mei 2026, 22:27 UTC

Winsten

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mei 2026, 22:27 UTC

Winsten

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mei 2026, 22:26 UTC

Winsten

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mei 2026, 22:25 UTC

Winsten

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

80.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.03 USD 80.94%

Hoogste 7 USD

Laagste 4 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.